Shots: BioLizard to develop an AI-based bioinformatics algorithm supporting the transition of its Immuno-Transcriptomic RT-PCR based product, Colox onto Novigenix’s LITOseek platform for early colon cancer detection as well as […]readmore
Tags : AI
Shots: Atomwise to receive technology access fees, option exercise fees, royalties, and income-based on sublicensing or sale of assets leading to a total deal value of ~$1.5B. The companies will […]readmore
Shots: Mayo Clinic signs 10yrs. agreement with Google to transform the future of healthcare and to hasten the pace of health care innovation via digital technologies. Google Cloud will be […]readmore
Shots: The new precision health app, LIFE Extend guides users to adopt five pillars of health which include physical activity, nutrition, mindfulness, sleep and intermittent fasting, enabling the in leading […]readmore
Shots: Medtronic to distribute Viz.ai’s LVO detection and triage software services to ~200 hospitals with the goal of making Viz.ai available to every stroke center in the US The focus […]readmore
Shots: IBM Watson has presented 22 new scientific studies showing progress in clinical studies of cancer using AI-Technology with informed decisions based on curated scientific evidences, insights and information which […]readmore
Shots: Celgene & Exscientia enter into a 3yrs. partnership to accelerate the development of small molecules for three therapeutic programs for Celgene using Exscientia’s Centaur Chemist AI drug discovery platform […]readmore
Shots: Merck KGaA enters into an agreement with Iktos to develop therapies using Iktos’ AI technology for three drug discovery projects The focus of the agreement is to develop and […]readmore
Shots: The BCI application focuses on human auditory cortex for the reconstruction of unspoken thoughts into speech for patients have who lost their ability to speak due to stroke, injury, […]readmore
Shots: The approval is based on clinical trials assessing Embrace in 141 patients including 80 pediatric with epilepsy aged 6 to 21 years (generalized tonic-clonic seizures) after winning clearance for […]readmore